Harman Patil (Editor)

Forodesine

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Formula
  
C11H14N4O4

Molar mass
  
266.25 g/mol

Forodesine httpsuploadwikimediaorgwikipediacommonsthu

Forodesine (INN; also known as Immucillin H) is a transition-state analog inhibitor of purine nucleoside phosphorylase studied for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and for treatment of B-cell acute lymphocytic leukemia (B-ALL).

Forodesine was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.

Forodesine is being developed by BioCryst Pharmaceuticals as Fodosine. As of 2008, it is currently in phase II clinical trials..

In 2006, BioCryst announced an licensing agreement with Mundipharma International Holdings Limited (“Mundipharma”) to develop and commercialize Fodosine in markets across Europe, Asia, and Australasia for use in oncology.

William p sheridan mb bs forodesine shows activity in a relapsed refractory chronic lymphocytic


References

Forodesine Wikipedia